Rituximab vs Ocrelizumab in Relapsing-Remitting Multiple SclerosisIzanne Roos, Vincent Van Pesch, Stella Hughes et al.|JAMA Neurology|2023Cited by 62
Standardized Definition of Progression Independent of Relapse Activity (PIRA) in Relapsing-Remitting Multiple SclerosisJannis Müller, Tomáš Kalinčík, Alexandre Prat et al.|JAMA Neurology|2025Cited by 43
Heterogeneity on long-term disability trajectories in patients with secondary progressive MS: a latent class analysis from Big MS Data networkAlessio Signori, Helmut Butzkueven, Johannes Lorscheider et al.|Journal of Neurology Neurosurgery & Psychiatry|2022Cited by 17
The effectiveness of natalizumab vs fingolimod–A comparison of international registry studiesJohanna Balslev Andersen, Gilles Edan, Sifat Sharmin et al.|Multiple Sclerosis and Related Disorders|2021Cited by 12
Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Subgroup Analysis From Three International CohortsSifat Sharmin, Éric Berger, Mathilde Lefort et al.|CNS Drugs|2021Cited by 12